2SEVENTY BIO
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
2SEVENTY BIO
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2021-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.2seventybio.com
Total Employee:
251+
Status:
Active
Contact:
617-675-7270
Email Addresses:
[email protected]
Total Funding:
170 M USD
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Cogent Biosciences
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Employees Featured
Stock Details
Investors List
Madison Avenue Partners
Madison Avenue Partners investment in Post-IPO Equity - 2seventy bio
Casdin Capital
Casdin Capital investment in Post-IPO Equity - 2seventy bio
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Post-IPO Equity - 2seventy bio
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - 2seventy bio
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - 2seventy bio
CaaS Capital Management
CaaS Capital Management investment in Post-IPO Equity - 2seventy bio
Newtyn Management
Newtyn Management investment in Post-IPO Equity - 2seventy bio
683 CAPITAL
683 CAPITAL investment in Post-IPO Equity - 2seventy bio
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - 2seventy bio
Heights Capital Management
Heights Capital Management investment in Post-IPO Equity - 2seventy bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-14 | 2seventy bio plucks Turnstone Biologics exec Bernstein to be new CMO |
Official Site Inspections
http://www.2seventybio.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.43 K
- Host name: 45.60.170.161
- IP address: 45.60.170.161
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "2seventy bio"
2seventy bio
Our name, 2seventy bio TM, is inspired by the maximum speed of translating human thought into action — 270 miles per hour. At 2seventy bio, we think in the language of time.See details»
Patients & Advocacy - 2seventy bio
At 2seventy bio, our approach is intimate and individual. We value your voice and what you have to share. To start a conversation, ask a question, or share your story, contact: …See details»
2seventy bio - Crunchbase Company Profile & Funding
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with …See details»
2seventy bio Completes Spin Transaction and …
Nov 4, 2021 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- 2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company....See details»
2seventy bio - LinkedIn
We are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. Our name, 2seventy bio, is inspired by the...See details»
2seventy bio Announces Completion of Oncology and …
Apr 1, 2024 · Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for …See details»
2Seventy Bio, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for 2Seventy Bio, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
JW Therapeutics and 2seventy bio Announce Strategic Partnership …
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing …See details»
2seventy splits again, sending cell therapy R&D to …
Jan 30, 2024 · Regeneron will fully acquire 2seventy’s dual-targeted CAR T cell therapy bbT369 in B-cell non-Hodgkin lymphoma, SC-DARIC33 in acute myeloid leukemia, MUC16 for ovarian cancer, MAGE-A4,...See details»
'Better than Abecma': Slimmed-down 2seventy charts …
Feb 24, 2022 · In many ways, 2seventy bio feels like a startup, according to CEO Nick Leschly. Entering its first full year as an independent company since formalizing a spinoff from bluebird bio to focus...See details»
2seventy bio Announces Key Management Appointments
Feb 14, 2022 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- 2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the …See details»
2seventy bio Announces New Strategic Path Forward | Nasdaq
Jan 30, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the …See details»
2seventy Sells Cell Therapy Operations to Regeneron, in Latest ...
Jan 30, 2024 · 2seventy bio has sold its cell therapy pipeline and operations to Regeneron Pharmaceuticals for at least $15 million, as part of a restructuring that includes eliminating …See details»
2seventy slims down with sale of hemophilia assets to Novo
Jun 27, 2024 · 2seventy Bio is shrinking further, announcing Thursday the sale of a hemophilia A research program, along with associated technology rights, to partner Novo Nordisk. 2seventy …See details»
2seventy bio Announces New Strategic Path Forward - Yahoo …
CAMBRIDGE, Mass., January 30, 2024 -- (BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the …See details»
2Seventy Bio Inc | Reuters
Apr 8, 2024 · Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they …See details»
Release Details - 2seventy bio
May 1, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--May 1, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it …See details»
2seventy bio Presents Broad Range of New Data Highlighting …
May 17, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--May 17, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new …See details»
2seventy bio Reports Third Quarter Financial Results and Recent ...
Nov 12, 2024 · 2seventy bio will host a conference call and live webcast today, November 12 at 8:00 a.m. ET to discuss third quarter 2024 financial results and recent business highlights.See details»
2seventy bio Reports Third Quarter Financial Results and Recent ...
Nov 12, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Nov. 12, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter …See details»